Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/63563
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype |
Autor: | Colado, Enrique; Álvarez-Fernández, Stela CSIC; Maiso, Patricia; Martín, Jesús; Vidriales, Maria Belén; Garayoa, Mercedes CSIC ORCID ; Ocio, Enrique M. CSIC ORCID ; Montero, Juan Carlos CSIC ORCID; Pandiella, Atanasio CSIC ORCID CVN ; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2008 | Editor: | Ferrata Storti Foundation | Citación: | Haematologica 93(1): 57-66 (2008) | Resumen: | [Background]: Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute myeloid leukemia (AML) is an immnunophenotypically heterogeneous group of diseases, with CD34+ cases being associated with drug resistance and poor outcome. We investigated the effects of bortezomib on the growth and survival of AML cells. [Design and Methods]: We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and fresh cells from 28 AML patients including CD34+ and CD34- cases. [Results]: Bortezomib showed potent anti-AML activity (IC50 < 50 nM), which was greater than that of conventional agents (doxorubicin, cytarabine and fludarabine). Moreover, synergistic effects were observed when bortezomib was adminstered in combination with doxorubicin and cytarabine. Mechanistically, bortezomib induced accumulation of cells in the G2/M phase, with up-regulation of p27, together with cell death through an increase in the mitochondrial outer membrane permeability involving caspase-dependent and -independent pathways. The apoptotic activity of bortezomib on fresh CD34 + blast cells from patients was similar to that observed on CD34 - blast cells. Importantly, bortezomib was significantly more active than doxorubicin in the immature CD34+ cells, while there were no differences in its action on CD34- cells. [Conclusions]: Bortezomib induces apoptosis in acute myeloid leukemia cells in vitro. Whether this drug might be useful in the treatment of patients with acute myeloid leukemia can be established only in ad hoc clinical trials. ©2008 Ferrata Storti Foundation. | Versión del editor: | http://dx.doi.org/10.3324/haematol.11666 | URI: | http://hdl.handle.net/10261/63563 | DOI: | 10.3324/haematol.11666 | Identificadores: | doi: 10.3324/haematol.11666 issn: 0390-6078 e-issn: 1592-8721 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
The effect of the proteasome.pdf | 440,21 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
30
checked on 10-abr-2024
SCOPUSTM
Citations
56
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
45
checked on 26-feb-2024
Page view(s)
480
checked on 17-abr-2024
Download(s)
295
checked on 17-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.